Recent News

• 03.06.2025 - HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
• 03.05.2025 - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
• 02.19.2025 - HUTCHMED to Announce 2024 Final Results

Recent Filings

• 03.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.03.2025 - EX-99.1 EX-99.1
• 02.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.28.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.19.2025 - EX-99.1 EX-99.1
• 01.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.28.2025 - EX-99.1 EX-99.1
• 01.14.2025 - EX-99.1 EX-99.1
• 01.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]